Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LGVN | PRESS-RELEASE | mixed | 6/10 | Longeveron announced updated results from its Phase 2b ELPIS II trial of laromestrocel in HLHS. The trial missed the pri | Oct 26, 2026 |
| OTLC | 8-K | neutral | 2/10 | Oncotelic Therapeutics filed an 8-K to report that its Chief Business Officer presented a research framework (Partitione | Oct 26, 2026 |
| AZTR | 8-K | neutral | 4/10 | Azitra announced positive ex vivo data for its ATR-COSF cosmetic product candidate, showing up to ~50% reduction in fine | Oct 26, 2026 |
| IDXX | INST-CLUSTER | neutral | 3/10 | Three asset managers added to IDXX positions in Q3 2026, totaling $43.2M in net buying, while two managers trimmed $69.4 | Oct 26, 2026 |
| WST | INST-CLUSTER | neutral | 3/10 | Four institutional asset managers added to WST positions in Q3 2026, totaling $11.8M in net buying, while three smaller | Oct 26, 2026 |
| EQ | PRESS-RELEASE | neutral | 4/10 | Equillium dosed the first subject in a Phase 1 trial of EQ504, an oral AhR modulator for inflammatory diseases, triggeri | Oct 26, 2026 |
| BAK | 6-K | bearish | 6/10 | Braskem filed a 6-K disclosing confidential restructuring proposals exchanged with bondholders in its out-of-court reorg | Oct 26, 2026 |
| APVO | 8-K | neutral | 4/10 | Aptevo Therapeutics announced that 10 of 47 (21%) evaluable frontline AML patients treated with mipletamig in combinatio | Oct 26, 2026 |
| TCRX | DEF 14A | bearish | 6/10 | TScan Therapeutics is holding a special meeting on November 20, 2026, to seek stockholder approval for a reverse stock s | Oct 26, 2026 |
| ORKA | 8-K | bullish | 6/10 | Oruka Therapeutics announced positive Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001 in moderate-to-seve | Oct 26, 2026 |
| RADX | 6-K | neutral | 4/10 | Radiopharm Theranostics announced it received $8 million from Rockford Capital under a funding facility secured against | Oct 26, 2026 |
| OPTH | 6-K | neutral | 3/10 | Optimi Health Corp. announced the establishment of a wholly owned Australian subsidiary, Optimi Australia Pty Ltd, to ha | Oct 26, 2026 |
| BOLD | 425 | neutral | 4/10 | Boundless Bio (BOLD) filed a Rule 425 communication attaching a Serapha Bio press release announcing positive interim sa | Oct 26, 2026 |
| XNCR | 8-K | bullish | 6/10 | Xencor presented updated Phase 1 results for XmAb819 (ENPP3 x CD3 bispecific) in advanced ccRCC at ESMO 2026, showing a | Oct 26, 2026 |
| TRAX | S-1 | neutral | 4/10 | First Tracks Biotherapeutics filed an S-1 registration statement for the resale of up to 6,106,870 shares of common stoc | Oct 26, 2026 |
| IMTX | 6-K | bullish | 5/10 | Immatics N.V. reported updated Phase 1b clinical data for its PRAME-targeted bispecific IMA402 and Phase 1 data for its | Oct 26, 2026 |
| QUCY | PRESS-RELEASE | neutral | 2/10 | Quantum Cyber presented its antenna technology at QuantumCT's Phase 3 Pilot Collaboration RFP Convening on Quantum Sensi | Oct 26, 2026 |
| XLO | PRESS-RELEASE | neutral | 4/10 | Xilio Therapeutics announced dosing of the first patient in a Phase 1/2 trial of XTX501, a PD-1/masked IL-2 bispecific, | Oct 26, 2026 |
| IMRX | PRESS-RELEASE | neutral | 3/10 | Immuneering presented a trial-in-progress poster at ESMO 2026 for its pivotal Phase 3 trial (MAPKeeper 301) evaluating a | Oct 26, 2026 |
| ABOS | 8-K | neutral | 6/10 | Acumen Pharmaceuticals reported Q3 2026 financial results with a net loss of $25.4 million ($0.35 per share), narrower t | Oct 26, 2026 |
| MGNX | PRESS-RELEASE | bullish | 6/10 | MacroGenics announced positive interim Phase 2 LINNET data for lorigerlimab in clear cell gynecologic cancer (CCGC), sho | Oct 26, 2026 |
| CANF | 6-K | neutral | 4/10 | Can-Fite BioPharma presented final Phase IIa data for namodenoson in advanced pancreatic cancer at ESMO 2026. The study | Oct 26, 2026 |
| ABOS | PRESS-RELEASE | neutral | 5/10 | Acumen Pharmaceuticals reported a Q3 2026 net loss of $25.4M ($0.35 per share), slightly narrower than the year-ago $26. | Oct 26, 2026 |
| REGN | PRESS-RELEASE | neutral | 3/10 | Regeneron expanded its existing BARDA procurement agreement for Inmazeb, its FDA-approved Ebola treatment, adding approx | Oct 26, 2026 |
| ZEOX | 8-K | neutral | 5/10 | Zeo ScientifiX (ZEOX) entered into a definitive strategic partnership agreement with Pluri Inc. (PLUR) to expand U.S. ma | Oct 26, 2026 |
| GSK | 6-K | bullish | 5/10 | GSK announced positive interim results from the phase II AZUR-1 trial of Jemperli (dostarlimab) monotherapy in MSI-H/dMM | Oct 26, 2026 |
| BNTX | 6-K | bullish | 5/10 | BioNTech and Bristol Myers Squibb reported encouraging Phase 2 data from the ROSETTA Lung-107 trial evaluating pumitamig | Oct 26, 2026 |
| SNY | 6-K | neutral | 2/10 | Sanofi broke ground on a new insulin manufacturing facility in Frankfurt, Germany, with full production of insulin activ | Oct 26, 2026 |
| GSK | 6-K | neutral | 4/10 | GSK announced updated Phase Ib data for its investigational ADC, Mo-Rez, in platinum-resistant ovarian cancer, showing a | Oct 26, 2026 |
| CLYM | 8-K | bullish | 6/10 | Climb Bio announced initial Phase 2 data from its PrisMN trial of budoprutug in primary membranous nephropathy (pMN) at | Oct 26, 2026 |